Signs of this disruption are already visible: Venture capital funding in digital health is skyrocketing; the millennial generation is making the leap from being tech-savvy consumers to being empowered patients while a growing number of policy initiatives are encouraging the use of technology to transform how we access, pay for and evaluate healthcare.
“We’ve already seen the impact of this transition from analog to digital in other industries,” says Francisco Rausa, AbbVie senior principal research scientist. “In healthcare, if we’re going to address future challenges like aging, treatment cost, and the demand for transparency, we need to catch up. Find disruptions or be disrupted!”
The implications are tremendous. From personalized medicine that treats the person, rather than the disease, to improved proactive patient-physician communication, technology has the power to dramatically improve outcomes and propel healthcare into the future.
But forging this link between healthcare and technology will require partnerships and collaborations that challenge convention and reward a “think outside the box” approach.
AbbVie has embraced this challenge, putting together a team focused exclusively on finding and investing in the people, ideas and technologies that will drive the future of healthcare. Internally, the group responds to the name “FT2,” which stands for Future Therapeutics and Technologies. Created by Jim Sullivan, AbbVie vice president of pharmaceutical discovery, and led by Steve England, AbbVie director and head of future therapeutics and technologies, FT2 is one of the driving forces behind AbbVie’s commitment to big-picture innovations in healthcare, from diagnosis to delivery.
The following are some of the ways AbbVie is uncovering opportunities at the intersection of health and technology: